Sign Out
In vitro studies indicate that Celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4. In vivo studies have shown the following: Lithium: In a study conducted in healthy subjects, mean steady-state Lithium plasma levels increased approximately 17% in subjects receiving Lithium 450 mg twice daily with Celecoxib 200 mg twice daily as compared to subjects receiving Lithium alone.
Fluconazole: Concomitant administration of Fluconazole at 200 mg once daily resulted in a two-fold increase in Celecoxib plasma concentration. This increase is due to the inhibition of Celecoxib metabolism via P450 2C9 by Fluconazole.
Other Drugs: The effects of Celecoxib on the pharmacokinetics and/or pharmacodynamics of Glyburide, Ketoconazole, Methotrexate, Phenytoin, and Tolbutamide have been studied in vivo and clinically important interactions have not been found.
Continue with Google